BR112012000380A2 - diagnóstico e tratamento de doenças autoimunes desmielinizante. - Google Patents

diagnóstico e tratamento de doenças autoimunes desmielinizante.

Info

Publication number
BR112012000380A2
BR112012000380A2 BR112012000380A BR112012000380A BR112012000380A2 BR 112012000380 A2 BR112012000380 A2 BR 112012000380A2 BR 112012000380 A BR112012000380 A BR 112012000380A BR 112012000380 A BR112012000380 A BR 112012000380A BR 112012000380 A2 BR112012000380 A2 BR 112012000380A2
Authority
BR
Brazil
Prior art keywords
diagnosis
treatment
autoimmune diseases
demyelinating autoimmune
demyelinating
Prior art date
Application number
BR112012000380A
Other languages
English (en)
Inventor
Van Lookeren Campagne Menno
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BR112012000380A2 publication Critical patent/BR112012000380A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Rehabilitation Therapy (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
BR112012000380A 2009-07-07 2010-07-02 diagnóstico e tratamento de doenças autoimunes desmielinizante. BR112012000380A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22351109P 2009-07-07 2009-07-07
PCT/US2010/040992 WO2011005715A1 (en) 2009-07-07 2010-07-02 Diagnosis and treatment of autoimmune demyelinating diseases

Publications (1)

Publication Number Publication Date
BR112012000380A2 true BR112012000380A2 (pt) 2017-02-07

Family

ID=42730512

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012000380A BR112012000380A2 (pt) 2009-07-07 2010-07-02 diagnóstico e tratamento de doenças autoimunes desmielinizante.

Country Status (12)

Country Link
US (1) US20120128698A1 (pt)
EP (1) EP2451843A1 (pt)
JP (1) JP2012532873A (pt)
KR (1) KR20120051002A (pt)
CN (1) CN102471381A (pt)
AU (1) AU2010270761A1 (pt)
BR (1) BR112012000380A2 (pt)
CA (1) CA2766737A1 (pt)
IL (1) IL217133A0 (pt)
MX (1) MX2012000417A (pt)
SG (1) SG177580A1 (pt)
WO (1) WO2011005715A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014185151A1 (ja) * 2013-05-13 2014-11-20 コニカミノルタ株式会社 細胞染色方法及びその方法に使用する検体採取管
JP6966944B2 (ja) * 2016-02-03 2021-11-17 国立感染症研究所長 ノロウイルスが増殖可能な遺伝子組換え培養細胞、及び、その用途
CA3044457C (en) 2016-11-22 2024-05-14 Dendrocyte Biotech Pty Ltd Anti-cd300f antibody and uses thereof
US20180252712A1 (en) * 2017-03-01 2018-09-06 Washington University Receptor for norovirus and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0479909B1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
CA2102511A1 (en) 1991-05-14 1992-11-15 Paul J. Higgins Heteroconjugate antibodies for treatment of hiv infection
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
EP0617706B1 (en) 1991-11-25 2001-10-17 Enzon, Inc. Multivalent antigen-binding proteins
DE69334255D1 (de) 1992-02-06 2009-02-12 Novartis Vaccines & Diagnostic Marker für Krebs und biosynthetisches Bindeprotein dafür
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
WO1994004690A1 (en) 1992-08-17 1994-03-03 Genentech, Inc. Bispecific immunoadhesins
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life

Also Published As

Publication number Publication date
WO2011005715A1 (en) 2011-01-13
MX2012000417A (es) 2012-02-08
JP2012532873A (ja) 2012-12-20
EP2451843A1 (en) 2012-05-16
SG177580A1 (en) 2012-03-29
IL217133A0 (en) 2012-02-29
AU2010270761A1 (en) 2012-01-19
CN102471381A (zh) 2012-05-23
CA2766737A1 (en) 2011-01-13
KR20120051002A (ko) 2012-05-21
US20120128698A1 (en) 2012-05-24

Similar Documents

Publication Publication Date Title
LTPA2017015I1 (lt) Apoptozę sukeliantys agentai, skirti vėžio ir imuninių ir autoimuninių ligų gydymui
BR112012002124A2 (pt) tratamento da doença de crohn com laquinimode.
EP2558493A4 (en) ANTIBODIES FOR THE TREATMENT OF INFECTION AND DISEASE ASSOCIATED WITH DIFFICULT CLOSTRIDIUM
BRPI0814624A2 (pt) Tratamento de doença neurodegenerativa progresiva com ibudilaste
BRPI0908026A2 (pt) Métodos para o tratamento de doenças do intestino
IT1391555B1 (it) Apparato trattamento extracorporeo sangue
BR112012002571A2 (pt) tratamento de minérios de titânio
EP2498796A4 (en) TREATMENT OF HEART DISEASES
HK1169455A1 (zh) 阿爾茨海默病的診斷和治療
BRPI0917567A2 (pt) tratamento de doença respiratória
ZA201301601B (en) Treatment of diseases
EP2613786A4 (en) TREATMENT OF DISEASES
BRPI0815551A2 (pt) Tratamento através de hucbc de doença beta-amiloide
GB0908193D0 (en) Treatment of disease state
GB0922085D0 (en) Cancer diagnosis and treatment
DK2627345T3 (da) Formuleringer til behandling af sygdomme i de øvre luftveje
SMT201600189B (it) Soluzione acquosa comprendente 3-chinuclidinoni per il trattamento di malattie iperproliferative, autoimmuni e cardiache
EP2548888A4 (en) SPECIFIC PEPTIDE OF PERIODONTAL PATHOLOGY AND TREATMENT AND DIAGNOSIS OF PERIODONTAL PATHOLOGY INCLUDING
GB0906159D0 (en) Drug combination for the treatment of proteostatic diseases
BRPI0908719A2 (pt) Metodos de diagnóstico, prevenção e tratamento de doenças de massa óssea
EP2563395A4 (en) TREATMENT WITH ANTI-S1P ANTIBODY OF PATIENTS WITH OCULAR DISEASES
DE102009018133A8 (de) Pharmazeutische Zusammensetzung zur Behandlung von dermatologischen Autoimmunerkrankungen
BR112012000380A2 (pt) diagnóstico e tratamento de doenças autoimunes desmielinizante.
EP2420515A4 (en) DIAGNOSIS AND TREATMENT OF CANCER USING ANTI-TMPRSS11E ANTIBODY
EP2556161A4 (en) METHODS OF TREATING AUTOIMMUNE DISEASES

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]